Table 1 Patient demographics and baseline clinical characteristics
From: Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Sex | Age | Duration of illness (years) | Baseline MMSE | Family history of AD | Comorbidities | Medications | |
|---|---|---|---|---|---|---|---|
Patient 1 | Male | 64 | 6 | 20 | No | Depressive symptoms, dyslipidemia, chronic obstructive pulmonary disease | Donepezil, rosuvastatin, sertraline |
Patient 2 | Male | 64 | 2 | 25 | No | Depressive symptoms, hypertension, dyslipidemia, mild obstructive sleep apnea | Donepezil, rosuvastatin, escitalopram |
Patient 3 | Female | 63 | ¼ | 22 | No | Depression, dyslipidemia, asthma | Donepezil, budesonide/formoterol, atorvastatin |
Patient 4 | Male | 78 | 3 | 25 | Dementia | Depressive symptoms | Omeprazole, meloxicam, escitalopram, donepezil |
Patient 5 | Female | 62 | 4 | 21 | Dementia | Depressive symptoms, hypertension, hyperlipidemia, inflammatory bowel disease, arthritis | Proranolol, perindopril, meloxicam, duloxetine, lansoprazole, atorvastatin, zopiclone, indapamide, donepezil |
Mean (SD) | 66.2 (6.6) | 3.1 (2.2) | 22.6 (2.3) |
